Results 71 to 80 of about 12,266 (204)

A Research Documentation On Men's Sexual Health Disclosed [PDF]

, 2010
When VigRX Plus was surveyed by Vedic Life-Sciences in proved to be the best pill treatment for sexual health.

core  

Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line [PDF]

, 2017
Phosphodiesterase 5A (PDE5A) specifically degrades the ubiquitous second messenger cGMP and experimental and clinical data highlight its important role in cardiac diseases.
Barbagallo, Federica, Campolo, Federica, Cardarelli, Silvia, Cornacchione, Marisa, DE ARCANGELIS, Valeria, DI GRAZIA, Antonio, Gianfrilli, Daniele, Giorgi, Mauro, Isidori, Andrea, Lenzi, Andrea, Monaco, Lucia, Naro, Fabio, Pellegrini, Manuela, Zevini, Alessandra   +13 more
core   +1 more source

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

BJU International, EarlyView.
Objectives To evaluate the efficacy and safety of a fixed‐dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). Patients and Methods This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom ...
Seung Wook Lee, Seung Hwan Lee, Jae Heon Kim, Joon Hwa Noh, Jun Ho Lee, U‐Syn Ha, Cheol Young Oh, Taek Won Kang, Gyeongseop Lee, Sangchul Lee, Deok Hyun Han, Jun Hyun Han, Sang Hoon Song, Hyun Jun Park, Byung Ha Chung, Gyeong Eun Min, In Gab Jeong, Kyung Hyun Moon, Won Tae Kim, Ji Youl Lee, Choung‐Soo Kim   +20 more
wiley   +1 more source

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review

International Journal of Retina and Vitreous, 2020
To provide information on the effects of phosphodiesterase type 5 (PDE5) inhibitors on choroidal vessels and central serous chorioretinopathy (CSC) and possible implications for development of exudative age-related macular degeneration (AMD).
Natasha Ferreira Santos da Cruz, Murilo Ubukata Polizelli, Laís Maia Cezar, Emmerson B. Cardoso, Fernando Penha, Michel Eid Farah, Eduardo B. Rodrigues, Eduardo A. Novais   +7 more
doaj   +1 more source

PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types [PDF]

, 2015
The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with a clinically relevant NSAID, celecoxib, to kill tumor cells.
Bastos-Pereira, Benavides, Booth, Booth, Bruzziches, Carón, Chandrasekharan, Chen, Chen, Choi, Chuang, Cremesti, Cruickshanks, Das, Das, Eberle, Florio, Flower, Formelli, Francis, Gandelman, Giannini, González, Grösch, Hamed, Hayden, Holliday, Hsieh, Hsu, Huang, Johnson, Kardosh, Kern, Kim, Komalavilas, Kots, Liu, Mao, Nandakishore, Nichols, Oh, Park, Park, Pilane, Piplani, Pyrko, Rabkin, Ramer, Reinehr, Roberts, Russwurm, Saba, Sabichi, Schiffmann, Schiffmann, Shen, Shin, Soh, Song, Swiergiel, Tang, Tripathi, Tsutsumi, Veronesi, Vosooghi, Wang, Watanabe, Werner, Williams, Yacoub, Yu   +70 more
core   +2 more sources

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

The current treatment of erectile dysfunction [PDF]

, 2016
Erectile dysfunction (ED) is the inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse. It is the most frequent sexual dysfunction in elderly men and its prevalence increases with age.
Benea, Vasile, Georgescu, Simona R., Mitran, Cristina I., Mitran, Mădălina I., Sarbu, Maria Isabela, Tampa, Mircea   +5 more
core   +2 more sources

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]

, 2018
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source